Mario Cruz‐Rivera

Statistics

Publications

Citations

949

H-Index

Active since

1998

Affiliations

AstraZeneca (United States)(Current)

University of Colorado Denver

National Jewish Health

Children's Hospital of Pittsburgh

Ann Arbor Center for Independent Living

Mario Cruz‐Rivera is an author at AstraZeneca (United States) specializing in budesonide therapy, suspension inhalation formulations, and pediatric pulmonology.

Publications per year

1998–2020

Publications

A Multiple-dosing, Placebo-controlled Study of Budesonide Inhalation Suspension Given Once or Twice Daily for Treatment of Persistent Asthma in Young Children and Infants

James Baker, Michael Mellon, Jeffrey Wald et al. · PEDIATRICS · 1999 · 200 citations

Pharmacy, Pediatrics, Pharmacology +17

Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid–dependent, persistent asthma

Gail Shapiro, Louis M. Mendelson, Michael J. Kraemer et al. · Journal of Allergy and Clinical Immunology · 1998 · 147 citations

Medicine, Child Health, Pediatrics +17

Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children

James P. Kemp, David P. Skoner, Stanley J. Szefler et al. · Annals of Allergy Asthma & Immunology · 1999 · 142 citations

Pharmacy, Child Health, Pediatrics +16

Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma

David P. Skoner, Stanley J. Szefler, Michael J. Welch et al. · Journal of Allergy and Clinical Immunology · 2000 · 79 citations

Medicine, Child Health, Pediatrics +17

Nebulized Budesonide Inhalation Suspension Compared With Cromolyn Sodium Nebulizer Solution for Asthma in Young Children: Results of a Randomized Outcomes Trial

Jeffrey Leflein, Stanley J. Szefler, Kevin R. Murphy et al. · PEDIATRICS · 2002 · 76 citations

Pharmacy, Pediatrics, Pharmacotherapy +17

1–5 of 16